{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-395694","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-09-18T21:00:21+00:00","discovered_at":"2026-09-18T21:02:13.237789+00:00","generated_at":"2026-09-18T21:02:33.026046+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Atossa updates corporate presentation on (Z)-Endoxifen, but no specifics disclosed","bullets":["Filed updated corporate presentation on 8-K Sept 18, 2026; no financial or clinical data shown.","Presentation cover cites (Z)-Endoxifen as potential best-in-class oral SERM/SERD for estrogen-driven diseases.","Available exhibit excerpt contains only the title slide; operational milestones or guidance not provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-395694","json":"https://secwatch.observer/filing/0001193125-26-395694.json","markdown":"https://secwatch.observer/filing/0001193125-26-395694.md","text":"https://secwatch.observer/filing/0001193125-26-395694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/0001193125-26-395694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/atos-20260918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-18T21:02:33.026046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}